10QSB 1 j0602801e10qsb.txt EQUIDYNE CORP. 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2004 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____ to _____ COMMISSION FILE NUMBER 0-9922 --------------- EQUIDYNE CORPORATION (Name of Small Business Issuer in Its Charter) DELAWARE 04-2608713 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation or Organization) 1620-400 BURRARD STREET, VANCOUVER, B.C., CANADA V6C 3A6 (Address of office) (Zip Code) Issuer's telephone number, including area code: (604) 408-8538 Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] YES [ ] NO The number of shares outstanding of the Company's common stock as at March 9, 2004 was 15,634,829. Transitional Small Business Disclosure Format (check one): [ ] YES [X] NO EQUIDYNE CORPORATION AND SUBSIDIARIES QUARTERLY REPORT - FORM 10-QSB THREE MONTHS ENDED JANUARY 31, 2004 TABLE OF CONTENTS PART I PAGE ----------------------------------------------------------------------- ---- Item 1. Consolidated Financial Statements 3-6 Item 2. Management's Discussion and Analysis or Plan of Operation 8-9 Item 3. Controls and Procedures 10 PART II Item 1. Legal Proceedings 10 Item 2. Changes in Securities and Use of Proceeds 10 Item 3. Defaults Upon Senior Securities 10 Item 4. Submission of Matters to a Vote of Security Holders 10 Item 5. Other Information 11 Item 6. Exhibits and Reports on Form 8-K 11 Signatures 12 FORWARD LOOKING STATEMENTS Certain statements contained in this Quarterly Report and other written material and oral statements made from time to time by us do not relate strictly to historical or current facts. As such, they are considered "forward-looking statements" that provide current expectations or forecasts of future events. Such statements are typically characterized by terminology such as "believe," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "strategy" and similar expressions. Our forward-looking statements generally relate to the prospects for our ability to identify new business opportunities, develop new business strategies to take advantage of such opportunities and execute such business strategies. These statements are based upon assumptions and assessments made by our management in light of its experience and its perception of historical trends, current conditions, expected future developments and other factors our management believes to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including the following: our ability to identify and evaluate business opportunities that will achieve profitable operations while maintaining sufficient cash to operate our business and meet our liquidity requirements: our ability to obtain financing, if required, on terms acceptable to us, if at all; our ability to successfully attract strategic partners and to market both new and existing products and services domestically and internationally; exposure to lawsuits and regulatory proceedings; governmental laws and regulations affecting domestic and foreign operations; our ability to identify and complete diversification opportunities; and the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items. Except as required by applicable law, the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. 2 PART I - FINANCIAL INFORMATION ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS EQUIDYNE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (DOLLARS IN THOUSANDS)
JANUARY 31, JULY 31, 2004 2003 ----------- -------- (UNAUDITED) ASSETS Current Assets: Cash and cash equivalents $ 11,199 $ 9,517 Accounts receivable, net -- 7 Inventories, net -- 66 Deferred costs -- 10 Refundable income taxes 3,611 6,441 Prepaid and other current assets 150 59 -------- -------- Total current assets 14,960 16,100 Property and equipment, net -- 50 Deposits 5 5 Patents, net -- 490 -------- -------- Total assets $ 14,965 $ 16,645 ======== ======== LIABILITIES & STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 401 $ 450 Accrued liabilities 914 913 Accrued income taxes 2,331 2,331 Deferred revenue -- 12 -------- -------- Total current liabilities 3,646 3,706 Commitments and contingencies Stockholders' Equity: Common stock 1,713 1,648 Additional paid-in capital 26,744 26,593 Accumulated deficit (11,825) (9,989) Treasury stock, at cost (5,313) (5,313) -------- -------- Total stockholders' equity 11,319 12,939 -------- -------- Total liabilities and stockholders' equity $ 14,965 $ 16,645 ======== ========
See accompanying notes. 3 EQUIDYNE CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
SIX MONTHS ENDED JANUARY 31, ------------------------- 2004 2003 ------- ------- Net sales $ 39 $ 51 Cost of goods sold 74 51 ------- ------- Gross loss (35) -- Selling, general and administrative expenses 2,044 1,715 Research and development -- 171 ------- ------- Total operating expenses 2,044 1,886 ------- ------- Operating loss (2,079) (1,886) Other income (expense): Interest and other 14 77 Gain (loss)on sale of property and equipment 229 (11) ------- ------- 243 66 ------- ------- Loss before income tax benefit (1,836) (1,820) Income tax benefit -- (541) ------- ------- Net loss $(1,836) $(1,279) ======= ======= Net loss per common share, basic and diluted $ (0.12) $ (0.09) ======= =======
See accompanying notes. 4 EQUIDYNE CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
THREE MONTHS ENDED JANUARY 31, ---------------------- 2004 2003 ------ ------ Net sales $ 37 $ 29 Cost of goods sold 55 26 ------ ------ Gross income (loss) (18) 3 Selling, general and administrative expenses 412 868 Research and development -- 90 ------ ------ Total operating expenses 412 958 ------ ------ Operating loss (430) (955) Other income (expense): Interest and other 5 24 Gain (loss)on sale of property and equipment 249 (11) ------ ------ 254 13 ------ ------ Loss before income tax benefit (176) (942) Income tax benefit -- (279) ------ ------ Net loss $ (176) $ (663) ====== ====== Net loss per common share, basic and diluted $(0.01) $(0.05) ====== ======
See accompanying notes. 5 EQUIDYNE CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)
SIX MONTHS ENDED JANUARY 31, --------------------------- 2004 2003 -------- -------- OPERATING ACTIVITIES: Net loss $ (1,836) $ (1,279) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 35 131 Deferred income taxes -- (546) Gain (Loss) on sale of property and equipment (229) 11 Changes in operating assets and liabilities: Accounts receivable 7 16 Refundable income taxes 2,830 -- Inventories 66 66 Other assets (81) (165) Accounts payable and other current liabilities (60) (434) -------- -------- Net cash provided by (used in) operating activities 732 (2,200) INVESTING ACTIVITIES: Proceeds from sale of property and equipment 734 4 Purchase of property and equipment -- (20) -------- -------- Net cash provided by (used in) investing activities 734 (16) FINANCING ACTIVITIES: Proceeds from exercise of stock options 216 -- -------- -------- Net cash provided by financing activities 216 -- -------- -------- Increase (decrease) in cash and cash equivalents 1,682 (2,216) Cash and cash equivalents, beginning of period 9,517 13,092 -------- -------- Cash and cash equivalents, end of period $ 11,199 $ 10,876 ======== ======== SUPPLEMENTAL CASH FLOW INFORMATION: Income taxes paid $ -- $ 295
See accompanying notes. 6 EQUIDYNE CORPORATION AND SUBSIDIARIES NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Equidyne Corporation (the "Company") is a holding company, which since its formation in 1977, has invested in various medical device companies and technologies. From January 1999 until January 2004, the Company had principally focused on the development of patented, needle-free drug delivery systems, principally the reusable INJEX(TM) System. In early 2002, the Company's executive management evaluated the Company's technologies, markets and production capabilities and concluded that a change in the strategic focus of the Company was necessary as the Company's production capabilities were not cost effective nor were its sales and marketing programs generating satisfactory results. The Company has since this time been in the process of evaluating strategic alternatives both within and outside of the medical products industry. In September 2003, after seeing the Company's executive management make little progress on developing the Company's needle-free business or other diversification opportunities, the stockholders of the Company voted to change the Board of Directors and executive management. As a result, the previous executive management team was replaced by the new Board of Directors. The new Board of Directors had three principal objectives: 1) minimize operating expenses; 2) further evaluate and realize value from its existing needle-free technologies; and 3) seek new business opportunities, investments and acquisitions not necessarily in the medical device field. On January 6, 2004, Equidyne Systems, Inc. ("ESI"), a wholly owned subsidiary of Equidyne Corporation, sold all its right, title and interest in and to its needle free technologies to HNS International Inc. ("HNS"). Basis of Presentation The interim period consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited consolidated financial statements and accompanying notes included in the Company's latest annual report on Form 10-KSB for the fiscal year ended July 31, 2003. In the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. The results for the periods presented herein may not be indicative of the results for any subsequent period or the entire year. 2. LOSS PER SHARE Basic loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the effect of dilutive securities, if any, principally stock options and warrants. Dilutive securities were not included in the calculation of diluted weighted average shares for the six month and three months ended January 31, 2004 and 2003, due to their anti-dilutive effect. The following table sets forth the computation of basic and diluted loss per share (in thousands, except per share amounts):
THREE MONTHS ENDED SIX MONTHS ENDED JANUARY 31, JANUARY 31, ------------------------ ------------------------ 2004 2003 2004 2003 -------- -------- -------- -------- Net loss $ (176) $ (663) $ (1,836) $ (1,279) ======== ======== ======== ======== Weighted-average shares 15,620 14,985 15,436 14,985 ======== ======== ======== ======== Net loss per share (Basic and Diluted) $ (0.01) $ (0.05) $ (0.12) $ (0.09) ======== ======== ======== ========
7 3. STOCK-BASED COMPENSATION In accordance with Statement No. 123, "Accounting for Stock-Based Compensation" ("FAS 123"), the Company accounts for its two stock option plans and other stock-based employee compensation using the intrinsic value method prescribed by Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations, as described more fully in the Company's annual report on Form 10KSB for the year ended July 31, 2003. Accordingly, compensation expense is recorded on the date of grant only to the extent the current market price of the underlying stock exceeds the option exercise price. The Company did not record any stock-based compensation expense in the six months ended January 31, 2004 and 2003. Had compensation expense been determined based on the fair values at dates of grant for its stock options under FAS 123, as amended by FAS 148, net loss and net loss per share would have been reported as indicated in the pro forma results below (in thousands, except per share amounts):
SIX MONTHS ENDED JANUARY 31, ------------------------- 2004 2003 ------- ------- Net loss, as reported $(1,836) $(1,279) Deduct: Stock-based employee compensation expense determined under fair value based method (507) (124) ------- ------- Pro forma net loss $(2,343) $(1,403) ======= ======= Net loss per share, as reported $ (0.12) $ (0.09) ======= ======= Net loss per share, pro forma $ (0.15) $ (0.09) ======= =======
The fair values under FAS 123 for options granted were estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: 2004 2003 ---- ---- Expected life (years) 3 3 Interest rate 4.0% 5.0% Volatility 0.95 0.94 Dividend yield 0.0% 0.0% ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION OVERVIEW The Company is a holding company, which since its formation in 1977 until January 2004, had invested in various medical device companies and technologies. In September 2003, after seeing the Company's executive management make little progress on developing the Company's needle-free business or other diversification opportunities, the stockholders of the Company overwhelmingly voted to change the Board of Directors and executive management. As a result, the previous executive management team was replaced by the new Board of Directors. The new Board of Directors had three principal objectives: 1) minimize operating expenses; 2) further evaluate and realize value from its existing needle-free technologies; and 3) seek new business opportunities, investments and acquisitions not necessarily in the medical device field. On January 6, 2004, Equidyne Systems, Inc. ("ESI"), a wholly owned subsidiary of Equidyne Corporation, sold all its right, title and interest in and to its needle free technologies to HNS International Inc. ("HNS") for $750,000. The Board of Directors continues to identify and evaluate potential business opportunities, investments and acquisitions. The following discussion and analysis of the results of operations and financial condition of the Company for the six months and three months ended January 31, 2004 should be read in conjunction with the consolidated financial statements and related notes included in this quarterly report, as well as the Company's most recent annual report on Form 10-KSB for the fiscal year ended July 31, 2003 filed with the U.S. Securities and Exchange Commission (the "SEC"). 8 RESULTS OF OPERATIONS - SIX MONTHS ENDED JANUARY 31, 2004 Consolidated net product sales ("sales") were $39,000 for the six months ended January 31, 2004 compared to $51,000 for the six months ended January 31, 2003, a decrease of $12,000, or 24%. The decrease in sales through the Company's distribution partners continues to reflect the Company's change in strategic focus and the effect of the cessation of most sales and marketing activities, including advertising and co-marketing expenditures prior fiscal year. Such sales and marketing expenditures have not proven to be effective in generating product sales. Cost of sales for the six months ended January 31, 2004 was $74,000, as compared to $51,000 in the six months ended January 31, 2003. The negative gross margin results from the production cost of the consumable components of the Company's products (the polycarbonate plastic ampules and vial adapters) which is in excess of the respective selling prices in the current fiscal period. Selling, general and administrative ("SG&A") expenses for the six months ended January 31, 2004 were $2,044,000, compared to $1,715,000 for the six months ended January 31, 2003, an increase of $329,000, or 19%. The increase in the current year principally reflects increased professional service fees and corporate expenditures associated with a proxy contest. The increase also reflects the payment of $150,000 for reimbursement of expenses and administrative and management fees to a Company with a common director. Research and development expenses decreased to $0 for the six months ended January 31, 2004 from $171,000 for the six months ended January 31, 2003 as the Company ceased its research and development activities in February 2003. The Company's income tax benefit for the six months ended January 31, 2003 was $541,000. The prior tax benefit was based on the Company's ability to carry back the operating losses incurred to recapture a portion of the taxes paid in fiscal year 2001. The Company recorded no income tax benefits in the current year. The Company cannot carry back fiscal 2004 losses and determined that it does not have sufficient taxable income available for future carry forward. Therefore, the Company believes it is appropriate to record a valuation allowance against its Federal and State deferred tax assets. RESULTS OF OPERATIONS - THREE MONTHS ENDED JANUARY 31, 2004 Consolidated net product sales ("sales") were $37,000 for the three months ended January 31, 2004 compared to $29,000 for the three months ended January 31, 2003, a increase of $8,000, or 28%. The increase is primarily the result of sale of inventories to HNS International Inc. Cost of sales for the three months ended January 31, 2004 was $55,000, as compared to $26,000 in the three months ended January 31, 2003. This represents an increase in cost of sales of 112%. The increase is primarily the result of sale of inventories to HNS International Inc. Selling, general and administrative ("SG&A") expenses for the three months ended January 31, 2004 were $412,000, compared to $868,000 for the three months ended January 31, 2003, a decrease of $456,000, or 53%. The Company paid $125,000 for reimbursement of expenses and administrative and management fees to a Company with a common director in the second quarter. Research and development expenses decreased to $0 for the three months ended January 31, 2004 from $90,000 for the three months ended January 31, 2003 as the Company ceased its research and development activities in February 2003. The Company's income tax benefit for the three months ended January 31, 2003 was $279,000. The prior tax benefit was based on the Company's ability to carry back the operating losses incurred to recapture a portion of the taxes paid in fiscal year 2001. The Company recorded no income tax benefits in the current year. The Company cannot carry back fiscal 2004 losses and determined that it does not have sufficient taxable income available for future carry forward. Therefore, the Company believes it is appropriate to record a valuation allowance against its Federal and State deferred tax assets. LIQUIDITY AND CAPITAL RESOURCES At January 31, 2004, the Company had working capital of $11.3 million, compared to working capital of $12.4 million at July 31, 2003. The decrease of approximately $1.1 million resulted primarily from the net effect of the Company's operating losses for the six months ended January 31, 2004 which was partially offset by proceeds received from the exercise of stock options and proceeds from sale of property and equipment. 9 The Company believes that funds on hand, combined with cash generated from investment income and tax refunds, will be sufficient to finance operations and capital expenditures for the next twelve months. In addition, the Company is seeking investments in or acquisitions of companies, technologies or products in related or other lines of business. There is no assurance that management will find suitable opportunities or effect the necessary financial arrangements for such investments or provide the working capital needed for the acquired activities. ITEM 3. CONTROLS AND PROCEDURES We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As of January 31, 2004, the end of the quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report at the reasonable assurance level. There has been no change in our internal controls over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting subsequent to the date the Chief Executive Officer and Chief Financial Officer completed their evaluation. PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS On October 22, 2003, the Company's former Chief Executive Officer (Marcus R. Rowan) and its former President (Mark C. Myers) brought claims against the Company in the District Court of Dallas County, Texas alleging breach of contract for failure to pay back wages, severance payments, accrued but unpaid vacation and certain health and welfare benefits under the terms of their respective employment arrangements. In addition, the plaintiffs allege defamation as it relates to their dismissal from the Company "for cause." The plaintiffs seek actual damages of approximately $281,000, plus unspecified amounts for exemplary damages and attorneys' fees. The Company denies such allegations and intends to vigorously defend against such claims. In the ordinary course of conducting its business, the Company may become subject to litigation and claims regarding various matters. There exists a reasonable possibility that the Company will not prevail in all cases. Although sufficient uncertainty exists in these cases to prevent the Company from determining the amount of its liability, if any, the ultimate exposure upon the resolution of any such litigation or claims is not expected to materially adversely affect the Company's financial condition or results of operations. ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS None. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDER None. ITEM 5. OTHER INFORMATION None. 10 ITEM 6. EXHIBITS AND REPORTS ON FORMS 8-K (a) Exhibits Exhibit 31.1 - Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 32.1 - Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (b) Reports on Form 8-K: On November 20, 2003, the Company filed a Report on Form 8-K to disclose the change in auditors. On December 19, 2003, the Company filed a Report on Form 8-K in relation to a press release announcing the Company's agreement with HNS International, Inc. related to sale of needle-free business. On January 10, 2004, the Company filed a Report on Form 8-K in relation to a press release announcing the sale of needle-free business. 11 SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EQUIDYNE CORPORATION Dated: March 12, 2004 By: /s/ Michael J. Smith ------------------------ Michael J. Smith Chief Executive Officer, President and Chief Financial Officer 12